Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

271 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Demographics, Epidemiology, Mortality, and Difficult-To-Treat Resistance Patterns of Bacterial Bloodstream Infections in the Global United States Military Health System from 2010-2019: A Retrospective Cohort Study.
Vostal AC, Grance M, Powers JH, Kadri SS, Warner S, Chukwuma U, Morales C, Lanteri C, Carson ML, Poitras B, Seliga N, Follmann D, Wang J, Parmelee E, Mende K. Vostal AC, et al. Among authors: follmann d. medRxiv [Preprint]. 2024 Oct 3:2024.10.02.24314780. doi: 10.1101/2024.10.02.24314780. medRxiv. 2024. PMID: 39802776 Free PMC article. Preprint.
Vector induced humoral responses after rVSVΔG-ZEBOV-GP immunization identify vaccinated individuals and correlate with Ebola virus glycoprotein antibodies.
Chandrasekaran P, Berry IM, Callier V, Anthony SM, Hensley K, Kuhn JH, Shaw-Saliba K, Kennedy SB, Kieh M, Browne SM, Crozier I, Davey RT, Lane HC, Hensley LE, Follmann DA. Chandrasekaran P, et al. Among authors: follmann da. J Infect Dis. 2024 Dec 24:jiae632. doi: 10.1093/infdis/jiae632. Online ahead of print. J Infect Dis. 2024. PMID: 39718991
Who to Boost When: The Effect of Age and Dosing Interval on Delta and Omicron COVID-19 Incidence in the Open-label Phase of the COVE Trial.
Follmann D, Wang X, Baden LR, El Sahly HM, Essink B, Gilbert P, Janes HE, Kelley CF, Berman MA, Frank I, Chu E, Deng W, Priddy F, Dixit A, Tomassini JE, Das R, Miller J, Zhou H. Follmann D, et al. Open Forum Infect Dis. 2024 Nov 25;11(12):ofae689. doi: 10.1093/ofid/ofae689. eCollection 2024 Dec. Open Forum Infect Dis. 2024. PMID: 39679349 Free PMC article.
Neutralizing antibody correlate of protection against severe-critical COVID-19 in the ENSEMBLE single-dose Ad26.COV2.S vaccine efficacy trial.
Carpp LN, Hyrien O, Fong Y, Benkeser D, Roels S, Stieh DJ, Van Dromme I, Van Roey GA, Kenny A, Huang Y, Carone M, McDermott AB, Houchens CR, Martins K, Jayashankar L, Castellino F, Amoa-Awua O, Basappa M, Flach B, Lin BC, Moore C, Naisan M, Naqvi M, Narpala S, O'Connell S, Mueller A, Serebryannyy L, Castro M, Wang J, Petropoulos CJ, Luedtke A, Lu Y, Yu C, Juraska M, Hejazi NS, Wolfe DN, Sadoff J, Gray GE, Grinsztejn B, Goepfert PA, Bekker LG, Gaur AH, Veloso VG, Randhawa AK, Andrasik MP, Hendriks J, Truyers C, Vandebosch A, Struyf F, Schuitemaker H, Douoguih M, Kublin JG, Corey L, Neuzil KM, Follmann D, Koup RA, Donis RO, Gilbert PB; Immune Assays Team; Coronavirus Vaccine Prevention Network (CoVPN)/ENSEMBLE Team; United States Government (USG)/CoVPN Biostatistics Team. Carpp LN, et al. Among authors: follmann d. Nat Commun. 2024 Nov 12;15(1):9785. doi: 10.1038/s41467-024-53727-y. Nat Commun. 2024. PMID: 39532861 Free PMC article. Clinical Trial.
Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial.
Fong Y, Dang L, Zhang B, Fintzi J, Chen S, Wang J, Rouphael NG, Branche AR, Diemert DJ, Falsey AR, Losada C, Baden LR, Frey SE, Whitaker JA, Little SJ, Kamidani S, Walter EB, Novak RM, Rupp R, Jackson LA, Yu C, Magaret CA, Molitor C, Borate B, Babu TM, Kottkamp AC, Luetkemeyer AF, Immergluck LC, Presti RM, Bäcker M, Winokur PL, Mahgoub SM, Goepfert PA, Fusco DN, Atmar RL, Posavad CM, Mu J, Makowski M, Makhene MK, Nayak SU, Roberts PC, Follmann D, Gilbert PB; Coronavirus Variant Immunologic Landscape Trial (COVAIL) Study Team. Fong Y, et al. Among authors: follmann d. Clin Infect Dis. 2024 Sep 26:ciae465. doi: 10.1093/cid/ciae465. Online ahead of print. Clin Infect Dis. 2024. PMID: 39325506
Omicron COVID-19 immune correlates analysis of a third dose of mRNA-1273 in the COVE trial.
Zhang B, Fong Y, Fintzi J, Chu E, Janes HE, Kenny A, Carone M, Benkeser D, van der Laan LWP, Deng W, Zhou H, Wang X, Lu Y, Yu C, Borate B, Chen H, Reeder I, Carpp LN, Houchens CR, Martins K, Jayashankar L, Huynh C, Fichtenbaum CJ, Kalams S, Gay CL, Andrasik MP, Kublin JG, Corey L, Neuzil KM, Priddy F, Das R, Girard B, El Sahly HM, Baden LR, Jones T, Donis RO, Koup RA, Gilbert PB, Follmann D; United States Government (USG) COVID-19 Immune Assays Team; Moderna, Inc. Team; Coronavirus Vaccine Prevention Network (CoVPN)/Coronavirus Efficacy (COVE) Team; USG/CoVPN Biostatistics Team. Zhang B, et al. Among authors: follmann d. Nat Commun. 2024 Sep 11;15(1):7954. doi: 10.1038/s41467-024-52348-9. Nat Commun. 2024. PMID: 39261482 Free PMC article. Clinical Trial.
Long-term safety and effectiveness of mRNA-1273 vaccine in adults: COVE trial open-label and booster phases.
Baden LR, El Sahly HM, Essink B, Follmann D, Hachigian G, Strout C, Overcash JS, Doblecki-Lewis S, Whitaker JA, Anderson EJ, Neuzil K, Corey L, Priddy F, Tomassini JE, Brown M, Girard B, Stolman D, Urdaneta V, Wang X, Deng W, Zhou H, Dixit A, Das R, Miller JM; COVE Trial Consortium. Baden LR, et al. Among authors: follmann d. Nat Commun. 2024 Aug 29;15(1):7469. doi: 10.1038/s41467-024-50376-z. Nat Commun. 2024. PMID: 39209823 Free PMC article. Clinical Trial.
Exposure proximal immune correlates analysis.
Huang Y, Follmann D. Huang Y, et al. Among authors: follmann d. Biostatistics. 2024 Aug 14:kxae031. doi: 10.1093/biostatistics/kxae031. Online ahead of print. Biostatistics. 2024. PMID: 39142660
271 results